Expression and prognostic significance of livin, caspase-3, and Ki-67 in the progression of human ampullary carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 525-531

  Xue, Dong ^a   Zuo, Kai ^b   Li, Xinjun ^c   Zhang, Tongjun ^a   Chen, Hongqiang ^a   Cheng, Yu ^a   Chen, Yuxin ^a  

^a SHANDONG UNIVERSITY   (China)

^b Departments of Infectious Diseases   (United Kingdom)

^c People's Hospital of Binzhou   (China)

Author keywords

Ampullary carcinoma; Immunohistochemistry; Ki 67; Livin caspase 3

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; LIVIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL NUCLEUS; CLINICAL FEATURE; COHORT ANALYSIS; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; TUMOR GROWTH; VATER PAPILLA CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AMPULLA OF VATER; CARCINOMA; CASPASE 3; COMMON BILE DUCT NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892433847     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31827da412     Document Type: Article

References (46)

1. Yamaguchi K, Enjoji M. Carcinoma of the ampulla of Vater: A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer. 1987;59:506-515.
2. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- To 10-year follow-up. Surgery. 2006;140:764-772.
3. Sakata J, Shirai Y, Wakai T, et al. Assessment of the nodal status in ampullary carcinoma: The number of positive lymph nodes versus the lymph node ratio. World J Surg. 2011;35:2118-2124.
4. Kim RD, Kundhal PS, McGilvray ID, et al. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg. 2006;202:112-119.
5. Castro SM, Kuhlmann KF, Van Heek NT, et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg. 2004;8:775-784.
6. Vucic D, Stennicke HR, Pisabarro MT, et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 2000;10:1359-1366.
7. Franklin MC, Kadkhodayan S, Ackerly H, et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry. 2003;42:8223-8231.
8. Lin JH, Deng G, Huang Q, et al. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun. 2000;279:820-831.
9. Chen L, Ren GS, Li F, et al. Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol. 2008;14:5749-5754.
10. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276:3238-3246.
11. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of livin, survivin and other apoptosisrelated genes in the progression of superficial bladder cancer. Ann Oncol. 2003;14:85-90.
12. Liu HB, Kong CZ, Zeng Y, et al. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol. 2009;27:277-283.
13. Kempkensteffen C, Hinz S, Christoph F, et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumor Biol. 2007;28:132-138.
14. Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, livin/ML-IAP in lung cancer. Clin Cancer Res. 2005;11:1000-1009.
15. Liu X, Wang A, Gao H, et al. Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma. Int J Oncol. 2012;41:1021-1028.
16. Wang TS, Ding QQ, Guo RH, et al. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNAmediated silencing of livin gene. Biomed Pharmacother. 2010;64: 333-338.
17. Wang X, Xu J, Ju S, et al. Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem. 2010;43:655-660.
18. Lopes RB, Gangeswaran R, McNeish IA, et al. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer. 2007;120:2344-2352.
19. Nedelcu T, Kubista B, Koller A, et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 2008;134:237-244.
20. Augello C, Caruso L, Maggioni M, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125-134.
21. Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of- A poptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol. 2005;8:621-629.
22. Liu B, Han M, Wen JK, et al. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett. 2007;250:168-176.
23. Liu Chuan, Wu Xiaohou, Luo Chunli, et al. Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cellvia a mechanism involving caspase 3. J Exp Clin Cancer Res. 2010;29:63-71.
24. Yang D, Song X, Zhang J, et al. Suppression of livin gene expression by siRNA leads to growth inhibition and apoptosis induction in human bladder cancer T24 cells. Biosci Biotechnol Biochem. 2010;74:1039-1044.
25. Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res. 2003;63:6340-6349.
26. Ma L, Huang Y, Song Z, et al. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ. 2006;13:2079-2088.
27. O'Neill AJ, Boran SA, O'Keane C, et al. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate. 2001;47:183-188.
28. Cakir E, Yilmaz A, Demirag F, et al. Prognostic significance of micropapillary pattern in lung adenocarcinoma and expression of apoptosis-related markers: caspase-3, bcl-2, and p53. APMIS. 2011;119:574-580.
29. Hsia JY, Chen CY, Chen JT, et al. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. EJSO. 2003;29:44-48.
30. Persad R, Liu C, Wu TT, et al. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol. 2004;17:861-867.
31. Nakagawara A, Nakamura Y, Ikeda H, et al. High levels of expression and nuclear localization of interleukin-1b converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 1997;57:4578-4584.
32. Koomagi R, Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Cancer Res. 2000;20:493-496.
33. Albores-Saavedra J, Henson DE, Klimstra DS. Tumor of the gallbladder, extrahepatic bile duct, and ampulla of Vater. In: Rosai J, Sobin L, eds. Atlas of Tumor Pathology Third series, Fascicle 27. Washington DC: Armed Forces Institute of Pathology; 2000:259-316.
34. Aaltonen LA. WHO Classification of Tumors: Pathology and Genetics of Tumors of Digestive System. Lyon: IARC Press; 2000:105-119.
35. Aloysius MM, Hewavisenthi SJ, Bates TE, et al. Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays. World J Surg. 2010;34:2115-2121.
36. Xiang Y, Yao H, Wang S, et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope. 2006;116: 126-130.
37. Woo SM, Ryu JK. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195-3201.
38. Hsu HP, Shan YS, Hsieh YH, et al. Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc. 2007; 106:432-443.
39. Chen WX, Xie QG, Zhang WF, et al. Multiple imaging techniques in the diagnosis of ampullary carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7:649-653.
40. Manta R, Conigliaro R, Castellani D, et al. Linear endoscopic ultrasonography vs. magnetic resonance imaging in ampullary tumors. World J Gastroenterol. 2010;16:5592-5597.
41. Farina F, Cappello F, Todaro M, et al. Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease. J Histochem Cytochem. 2000;48:57-62.
42. Li YH, Wang C, Meng K, et al. Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol. 2004;10:1984-1988.
43. Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: A clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol. 2000;13:1300-1307.
44. Chang H, Schimmer AD. Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther. 2007;6:24-30.
45. Kasof GM, Prosser JC, Liu D, et al. The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria. FEBS Lett. 2000;473:285-291.
46. Yu L, Wang Z. Effects of Livin gene RNA interference on apoptosis of cervical cancer Hela cells and enhanced sensitivity to cisplatin. J Huazhong Univ Sci Technolog Med Sci. 2009;29:625-630.